Aptcash Enterprises
Parel, Mumbai, Maharashtra
SEND SMS
SEND EMAIL

Oncquest laboratory ltd

Diagnostic center is a place where different medical examinations are carried. A diagnosis or medical examinations are done on patient to check whether the body is carrying any disease or symptoms. Based on the diagnosis, treatment is given to the patient accordingly.

Oncquest is a well known testing lab which has its Pathology diagnostic labs in Mumbai and other parts of India. We at Oncquest are delivering over 30 million tests a year, catering to more than 20,000 medical Laboratories, Hospitals, Nursing homes and 2,00,000 Consultants.

We are a dynamic and constantly improving laboratory center, providing reliable pathology services to our clients and patients. We strive to produce extremely satisfactory results by keeping in touch with the latest developments in the field of pathology

We implement the latest technology available and our labs are equipped with molecular technology including fields such as bioinformatics, pharmocogenomics, companion diagnostics, proteomics and biomarker studies. We are also equipped with an integrated research facility and an advanced genetic oncology wing, thus expanding our scope of testing.

We are a certified and accredited cancer diagnosis lab by the National Accreditation Board for Testing and Calibration Laboratories (NABL) and College of American Pathology (CAP).

Oncquest Laboratories Ltd. – Mumbai

FoundationOne Heme

Approx. Price: Rs 3.1 Lakh / UnitGet Latest Price

Product Details:

Minimum Order Quantity1 Unit
Testing Typecancer

What is FoundationOne Heme?

FoundationOne Heme is a comprehensive genomic profiling test for hematologic malignancies and sarcomas. The test is designed to provide physicians with clinically actionable information to help with diagnostic subclassification, prognosis assessment, and targeted therapeutic selection. Test results provide information about clinically relevant alterations, potential targeted therapies, available clinical trials, and quantitative biomarkers that may support immunotherapy clinical trial enrollment.

FoundationOne Heme is validated to detect the four main classes of genomic alterations in more than 400 cancer-related genes. In addition to DNA sequencing, FoundationOne Heme employs RNA sequencing across more than 250 genes to capture a broad range of gene fusions, common drivers of hematologic malignancies, and sarcomas.

  • >400

    genes interrogated

  • >30

    select introns profiled

  • >250

    RNA-sequenced genes

  1. A single test that detects the four main classes of genomic alterations for hematologic cancers and sarcomas
  2. Uses both DNA and RNA sequencing for sensitive detection of translocations and fusions
  3. Reports tumor mutational burden (TMB) and microsatellite instability (MSI), which may inform clinical decision making and clinical trial enrollment

 

Request
Callback
Get Best Quote
Yes! I am Interested

MammaPrint Test Combination

Approx. Price: Rs 3.5 Lakh / UnitGet Latest Price

Product Details:

Minimum Order Quantity1 Unit
Service Chargescancer

The MammaPrint is a genomic test that analyzes the activity of certain genes in early-stage breast cancer. The MammaPrint Test is used in two ways:

  • Research suggests the MammaPrint test eventually may be used to estimate a woman’s recurrence risk for early-stage breast cancer that is hormone-receptor-positive or hormone-receptor-negative.
  • The MammaPrint test analyzes 70 genes using a microarray-based gene expression profile to see how active they are and then calculates either a high-risk or a low-risk recurrence score

Who’s eligible for the MammaPrint test?

MammaPrint can only be used to analyze early-stage breast cancers that are:

  • Stage I or stage II
  • Invasive
  • Smaller than 5 centimeters
  • Estrogen-receptor-positive or -negative

In both the United States and internationally, MammaPrint can be used to analyze cancers that are hormone-receptor-positive and hormone-receptor-negative.

How does the MammaPrint test work?

The MammaPrint test looks at the activity of 70 genes and then calculates a recurrence score that is either low risk or high risk.

If a patient decide to have the MammaPrint test, a patient and a patient’s doctor will consider a number of factors when deciding on whether to add chemotherapy to a patient treatment plan, including:

  • A patient age
  • The size of the cancer
  • Cancer grade
  • Whether cancer cells were found in nearby lymph nodes
  • A patient general health
Request
Callback
Get Best Quote
Yes! I am Interested

Cancer HOT SPOT Panel (50 Genes by NGS)

Approx. Price: Rs 2.6 Lakh / UnitGet Latest Price

Product Details:

Minimum Order Quantity1 Unit
Service Chargescancer

Cancer HOT SPOT Panel – 50 Genes by NGS
  • Allows translational and disease researchers to fast track oncology research by surveying hotspot regions of 50 oncogenes and tumor suppressor genes with wide coverage of many genes including KRAS, BRAF and EGFR genes.
  • Breakthrough technology with improved primer design, containing 207 primer pairs in a single tube and requires as little as 10ng of DNA, enabling researchers to sequence challenging samples such as formalin-fixed and paraffin-embedded (FFPE) tissue (, which are typically available only in small amounts and often exhibit variable quality).
  • Help in targeted therapy, reducing costs and improving the outcome of therapy
  • Very significant in cases where the patient has failed 1st / 2nd line of therapy or there has been no actionable mutation from the preliminary testing
  • A comprehensive information of the actionable mutations at the outset can help in timely treatment
    Helpful when trying to enrol the patient for clinical trials

Next Generation Sequencing (NGS)

A highly sensitive technology, which can detect mutations in samples having as low as 5% tumor cells. It can be multiplexed that is many genes can be targeted at the same time, thus detecting various mutations in the same assay. Each DNA nucleotide is read several times (100-1000 times) which adds to the specificity of the assay. This platform provides accurate, reliable data and excellent coverage.

Advantages of NGS

  • All at Once Approach for Cancer Diagnostics
  • NGS captures a broader spectrum of mutations
  • Comprehensive view of the most “actionable mutations” in solid tumors with greater in depth coverage,
    thus leading to enhanced sensitivity
  • The increased sensitivity of NGS allows detection of mosaic mutations
  • As low as 5% of mutant DNA can be detected, hence very low amount of DNA (~10 -50ng) as specimen is required
  • Faster TAT as compared to sequential gene testing using conventional methods
Request
Callback
Get Best Quote
Yes! I am Interested
View PDF

Foundation One Diagnostic Lab

Approx. Price: Rs 3.5 Lakh / UnitGet Latest Price

Product Details:

Minimum Order Quantity1 Unit
Service Chargescancer

FoundationOne® is a fully informative Comprehensive Genomic Profile from Foundation Medicine, Inc. that complements traditional cancer treatment decision tools. FoundationOne® often expands treatment options by matching patients with targeted therapies and clinical trials that are relevant to the molecular changes in their tumor based on the most recent scientific and medical published evidence. Results are provided in a user-friendly interpretive report. FoundationOne® utilizes proprietary next-generation sequencing techniques to identify all classes of alterations in genes known to be somatically altered in solid tumor cancers.

Foundation one (solid tumors)
  • Comprehensive genomic profile that interrogates the entire coding sequence of 315 cancer-related genes plus select introns from 28 genes often rearranged or altered in solid tumor cancers.
  • Identifies all classes of genomic alterations, including base pair substitutions, insertions and deletions, copy number alterations and select gene rearrangements.
  • Identify clinically relevant genomic alterations associated with targeted therapies
  • Quantify clinical markers associated with immunotherapy response

    Foundation one Heme (hematology malignancies & sarcomas)
    • Comprehensive genomic profile for hematologic cancers (leukemia, lymphoma and myeloma) and sarcomas.
    • Designed to provide physicians with clinically actionable information relevant for diagnosis, risk-stratification and prognosis to guide treatment options for patients based on the genomic profile of their cancer.
    • Assess routine cancer specimens for all genes that are currently known to be somatically altered in hematologic malignancies and sarcomas.
    • Simultaneously detects all classes of genomic alterations, including base pair substitutions, insertions and deletions, copy number alterations and select gene rearrangements in 405 cancer-related genes.
    • Also employs RNA sequencing across 265 genes to capture a broad range of gene fusions, a type of alteration that is a common driver of hematologic cancers and sarcomas.
    Request
    Callback
    Get Best Quote
    Yes! I am Interested
    X

    Explore more products



    Reach Us
    Deepak More (Proprietor)
    Shop No. 7, B Wing, Nirmala Niwas Aai Mai Merwanji Road
    Parel, Mumbai- 400012, Maharashtra, India



    Call Us

    Share Us

    F GT L


    Send E-mailSend SMS